SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-004029
Filing Date
2020-02-14
Accepted
2020-02-14 17:30:53
Documents
46
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20191231.htm   iXBRL 10-Q 699399
7 EXHIBITS 31.1 ex311_1.htm EX-31.1 16622
8 EXHIBITS 32.1 ex321_2.htm EX-32.1 6191
  Complete submission text file 0001213900-20-004029.txt   4418254

Data Files

Seq Description Document Type Size
2 SCHEMA rasp-20191231.xsd EX-101.SCH 51354
3 CALCULATION rasp-20191231_cal.xml EX-101.CAL 49111
4 DEFINITION rasp-20191231_def.xml EX-101.DEF 260712
5 LABEL rasp-20191231_lab.xml EX-101.LAB 830706
6 PRESENTATION rasp-20191231_pre.xml EX-101.PRE 416570
26 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20191231_htm.xml XML 449530
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 20622155
SIC: 2834 Pharmaceutical Preparations